Integra LifeSciences (NASDAQ:IART – Get Free Report) and Embecta (NASDAQ:EMBC – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, risk, valuation, analyst recommendations, profitability, institutional ownership and earnings.
Volatility and Risk
Integra LifeSciences has a beta of 1.21, suggesting that its share price is 21% more volatile than the S&P 500. Comparatively, Embecta has a beta of 0.84, suggesting that its share price is 16% less volatile than the S&P 500.
Institutional & Insider Ownership
84.8% of Integra LifeSciences shares are held by institutional investors. Comparatively, 93.8% of Embecta shares are held by institutional investors. 3.8% of Integra LifeSciences shares are held by company insiders. Comparatively, 1.3% of Embecta shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Profitability
This table compares Integra LifeSciences and Embecta’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Integra LifeSciences | 0.79% | 18.74% | 5.46% |
| Embecta | 8.59% | -19.25% | 10.82% |
Earnings and Valuation
This table compares Integra LifeSciences and Embecta”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Integra LifeSciences | $1.64 billion | 0.57 | -$516.47 million | $0.17 | 70.44 |
| Embecta | $1.08 billion | 0.34 | $95.40 million | $1.48 | 4.40 |
Embecta has lower revenue, but higher earnings than Integra LifeSciences. Embecta is trading at a lower price-to-earnings ratio than Integra LifeSciences, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of current recommendations and price targets for Integra LifeSciences and Embecta, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Integra LifeSciences | 2 | 5 | 2 | 0 | 2.00 |
| Embecta | 2 | 3 | 0 | 0 | 1.60 |
Integra LifeSciences presently has a consensus target price of $16.12, indicating a potential upside of 34.66%. Embecta has a consensus target price of $11.00, indicating a potential upside of 68.84%. Given Embecta’s higher possible upside, analysts plainly believe Embecta is more favorable than Integra LifeSciences.
Summary
Integra LifeSciences beats Embecta on 8 of the 14 factors compared between the two stocks.
About Integra LifeSciences
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services. It also sells instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute wounds; and surgical tissue repair products for hernia, tendon, peripheral nerve repair and protection. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.
About Embecta
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.
Receive News & Ratings for Integra LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png){kind=logo}
